John M. Dineen
CIK 1645270 · last filed 2026-08-27
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
MACK price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 36, 6TH FLOOR
TEANECK, NJ 07666
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CTSH | Director | 1,827 | $69.00 | $126.1K | $0 | 24 | 2026-08-27 |
| LRCX | Director | 9,135 | $262.33 | $2.40M | $0 | 3 | 2025-11-10 |
| Syneos Health, Inc. (SYNH) Delisted | Director | 0 | $42.98 | $0 | $513.7K | 8 | 2023-09-28 |
| MERRIMACK PHARMACEUTICALS INC (MACK) Delisted | Director | 10,000 | $15.13 | $151.3K | $1.01M | 5 | 2018-06-15 |
Recent Filings · Page 4 of 4
40 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-05-29 | Syneos Health, Inc. (SYNH) Delisted | Grant (A) | +4,122 | $175.0K | EDGAR |
| 2018-12-11 | Syneos Health, Inc. (SYNH) Delisted | Grant (A) | +1,630 | $0 | EDGAR |
| 2018-06-15 | MERRIMACK PHARMACEUTICALS INC (MACK) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-06-07 | CTSH | Grant (A) | — | $0 | EDGAR |
| 2017-09-15 | MERRIMACK PHARMACEUTICALS INC (MACK) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-06-09 | CTSH | Grant (A) | — | $0 | EDGAR |
| 2017-04-04 | CTSH | Grant (A) | — | $0 | EDGAR |
| 2016-06-16 | MERRIMACK PHARMACEUTICALS INC (MACK) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-08-13 | MERRIMACK PHARMACEUTICALS INC (MACK) Delisted | Buy (P) | +100,000 | $1.01M | EDGAR |
| 2015-06-16 | MERRIMACK PHARMACEUTICALS INC (MACK) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.